Skip to main content
VYNE Therapeutics Inc. logo

VYNE Therapeutics Inc. — Investor Relations & Filings

Ticker · VYNE ISIN · US92941V1008 US Manufacturing
Open in API
Filings indexed 608 across all filing types
Latest filing 2020-10-01 Regulatory Filings
Country US United States of America
Listing US VYNE

About VYNE Therapeutics Inc.

https://vynetherapeutics.com/

VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions. The company's primary objective is to address unmet medical needs by advancing a pipeline of novel drug candidates. VYNE's approach centers on innovating beyond traditional assumptions to find improved solutions for patients with complex inflammatory and immunological diseases.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text includes a press release about a product availability and states that the information is being furnished and not filed, which is typical for Regulation FD disclosures. There are no financial statements or detailed financial data included, and the document is relatively short (3953 characters). This is not an annual or quarterly report, nor an earnings release. It is a regulatory filing reporting a material event. Therefore, the appropriate classification is Regulatory Filings (RNS).
2020-10-01 English
FORM 4 SUBMISSION
Director's Dealing
2020-09-14 English
FORM 3 SUBMISSION
Director's Dealing
2020-09-14 English
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated September 8, 2020, for VYNE Therapeutics Inc. It reports the appointment of a new director to the Board of Directors, Mr. Patrick G. LePore, including details about his background and compensation. The document also references an attached press release and an investor presentation. The primary content is about a change in the company's board of directors. According to the filing definitions, announcements of changes in the company's board of directors or senior management fall under the category 'Board/Management Information' (MANG). The document is not a full annual report, earnings release, or other financial report, but a current report focused on management changes. Therefore, the appropriate classification is MANG with high confidence.
2020-09-14 English
FORM 4 SUBMISSION
Director's Dealing
2020-09-09 English
FORM 4 SUBMISSION
Director's Dealing
2020-09-09 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.